Page 4 - பெருநிறுவன வாழ்க்கைத்தொழில்கள் அரசு உறவுகள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share this article Share this article DUBLIN, April 22, 2021 /PRNewswire/  Jazz Pharmaceuticals plc (Nasdaq: JAZZ) (the Company or Jazz ) today announced the pricing of the previously announced offering (the Offering ) of $1.5 billion in an aggregate principal amount of 4.375% senior secured notes due 2029 (the Notes ) by Jazz Securities Designated Activity Company, a direct wholly owned subsidiary of the Company (the Issuer ). The Notes will mature on January 15, 2029 and will bear an interest rate of 4.375%. The Notes will be guaranteed by the Company and certain of its subsidiaries. The Offering is expected to close on April 29, 2021 subject to customary closing conditions. The aggregate principal amount of the Notes to be issued in the Offering decreased to $1.5 billion from the anticipated $2.7 billion announced on April 20, 2021, a decrease of $1.2 billion. This reduction corresponds to the equivalent anticipated increase in term loan borrowings under our new senior

United statesUnited kingdomJacqueline kirbyAndrean flynnEpidiolex epidyolexCorporate affairs government relationsJazz pharmaceuticalsCompany or jazzGw pharmaceuticalsExchange commissionCompany the issuerJazz securities designated activity companyHigh courtSenior secured creditNew senior secured credit facilitiesTransaction agreement